These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 808808)

  • 1. [Changes in the incidence of microscopically positive findings along with negative culture of M. tuberculosis in patients treated with rifampicin].
    Popovic I; Begovic N
    Plucne Bolesti Tuberk; 1975; 27(1-2):47-52. PubMed ID: 808808
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rifampicin and positive microscopic findings in a negative Mycobacterium tuberculosis culture].
    Begović N; Drinković I; Popović I
    Plucne Bolesti Tuberk; 1972; 24(3):157-62. PubMed ID: 4632836
    [No Abstract]   [Full Text] [Related]  

  • 3. [Clinical studies on the bacterial resistance to rifampicin].
    Sakurai H; Inoue I; Yamagami K
    Kekkaku; 1972 Dec; 47(12):475-9. PubMed ID: 4631478
    [No Abstract]   [Full Text] [Related]  

  • 4. [Rifampicin in the treatment of patients with chronic destructive tuberculosis complicated by drug intolerance and Mycobacterium drug resistance].
    Adamovich VN; Kolomytseva OS; Gur'ian IE
    Vrach Delo; 1975 Jan; (1):95-9. PubMed ID: 806177
    [No Abstract]   [Full Text] [Related]  

  • 5. [Investigation on failures in the treatment of pulmonary tuberculosis with rifampicin. Tuberculosis Research Committee. RYOKEN].
    Kekkaku; 1984 Feb; 59(2):91-104. PubMed ID: 6431172
    [No Abstract]   [Full Text] [Related]  

  • 6. Rifampicin in the retreatment and original treatment of advanced pulmonary tuberculosis.
    Gyselen A
    Bull Int Union Tuberc; 1970 Jun; 43():60-3. PubMed ID: 4987555
    [No Abstract]   [Full Text] [Related]  

  • 7. [Rifampicin and its sodium salt in experimental tuberculosis of albino mice].
    Pershin GN; Kutchek SN; Zykova TN
    Farmakol Toksikol; 1972; 35(3):342-7. PubMed ID: 4625834
    [No Abstract]   [Full Text] [Related]  

  • 8. [Dynamics of rifampicin and ethambutol resistance of strains of Koch bacilli isolated from patients with pulmonary tuberculosis 1973-1981].
    Ionescu C; Timoşca S; Petreanu V; Petreanu C; Georgescu M; Martinescu T
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1982; 31(4):315-20. PubMed ID: 6304845
    [No Abstract]   [Full Text] [Related]  

  • 9. [Survival of tuberculous bacilli in combined treatments including rifampicin].
    Kreis B; Pretet S
    Rev Tuberc Pneumol (Paris); 1970; 34(3):429-33. PubMed ID: 4994940
    [No Abstract]   [Full Text] [Related]  

  • 10. Rapid detection of smear-negative Mycobacterium tuberculosis by PCR and sequencing for rifampin resistance with DNA extracted directly from slides.
    Patnaik M; Liegmann K; Peter JB
    J Clin Microbiol; 2001 Jan; 39(1):51-2. PubMed ID: 11136747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental and clinical studies of rifampicin in tuberculosis.
    Konno K; Oizumi K; Hayashi I; Oka S
    Sci Rep Res Inst Tohoku Univ Med; 1970 Dec; 17(3):110-20. PubMed ID: 5004309
    [No Abstract]   [Full Text] [Related]  

  • 12. [Study of tuberculostatic activity and blood concentration of new agents--rifampicin and ethambutol--in patients with pulmonary tuberculosis].
    Mkrtchian SV; Ushkin VV
    Antibiotiki; 1971 May; 16(5):472-7. PubMed ID: 5002224
    [No Abstract]   [Full Text] [Related]  

  • 13. [The clinical significance of the critical drug concentration of rifampicin. Report 2. Clinical investigation: the emergence and reversion of resistance (author's transl)].
    Baba H; Azuma Y
    Kekkaku; 1976 Jan; 51(1):7-12. PubMed ID: 815710
    [No Abstract]   [Full Text] [Related]  

  • 14. [The critical concentration of clinical rifampicin resistance for tubercle bacilli and the acquirement pattern of rifampicin resistance of tubercle bacilli on Kirchner's semi-liquid agar media].
    Tamura M; Yamazaki A; Tamura T; Takano S; Yamazaki M
    Kekkaku; 1973 Jun; 48(6):247-53. PubMed ID: 4200023
    [No Abstract]   [Full Text] [Related]  

  • 15. [The sensitivity of Mycobacterium tuberculosis to rifampicin and its clinical effectiveness (author's transl)].
    Chen HL
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1980 Feb; 3(2):104-5. PubMed ID: 6774865
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical effects of rifampicin for pulmonary tuberculosis patients. 2. Results of rifampicin treatment for advanced pulmonary tuberculosis patients resistant to conventional antituberculous drugs].
    Kekkaku; 1971 Nov; 46(11):423-8. PubMed ID: 4335256
    [No Abstract]   [Full Text] [Related]  

  • 17. [Activity of the second-line preparations, ethambutol and rifampin, in experimental tuberculosis caused by Mycobacterium tuberculosis highly resistant to basic tuberculostatics].
    Golyshevskaia VI; El'shanskaia MP
    Probl Tuberk; 1973; 51(12):60-4. PubMed ID: 4205666
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical significance of drug resistance of tuberculosis mycobacteria and L-forms].
    Golanov VS; Bogdalova VE; Andreev LP; Losin EI; Ushakova AG; Meshcheriakov VG; Bondin SV
    Probl Tuberk; 1991; (12):27-8. PubMed ID: 1803368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes in the bacteriologic findings in patients treated with rifomycin, alone or associated with other drugs].
    Delli Veneri F; Centrella G; Stefanelli R
    Arch Tisiol Mal Appar Respir; 1968 May; 23(5):387-98. PubMed ID: 4979475
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapeutic failure in the application of rifampin (RFP): evaluation and management].
    Yamazaki M
    Kekkaku; 1983 Sep; 58(9):498-501. PubMed ID: 6420604
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.